Exagen Announces Five-Week Campaign for Lupus Awareness Month
May 01 2022 - 12:00PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced, in recognition of
Lupus Awareness Month, the launch of a five-week awareness campaign
to highlight important and impactful work being done to help those
suffering from Systemic Lupus Erythematosus (SLE).
For each of the five weeks in the month of May, Exagen will
focus on a different theme that, when combined, provides a holistic
view of the work being done within the lupus community. These
themes include:
- Diagnosis:
highlighting the role and importance of an early and accurate
diagnosis.
- Advocacy: sharing
the stories of patient advocates, and their impact on the
community.
- Community: shedding
light on the regional and local efforts bringing people
together.
- Research: providing
insight into the future of lupus diagnostics and therapies.
- Motivation:
spreading encouragement to those suffering from lupus.
To better deliver on these initiatives, and to properly shed
light on the challenges those with lupus face, Exagen is partnering
with the Lupus Foundation of America, Lupus LA, and patient
advocates throughout the month.
Ron Rocca, President and CEO of Exagen, shared, “The landscape
of lupus therapies and testing has changed over the past few years.
We’re in a position now where we can make a real impact for those
suffering from lupus, not only through a shorter diagnosis
timeframe, but with a more individualized approach. Spreading
awareness of what that impact looks like is imperative. We are
thrilled to be working with our partners to promote that
awareness.”
Interested in learning more? Visit AviseTest.com/patient for
helpful resources or follow Exagen social media platforms here:
Facebook, Instagram, LinkedIn, Twitter.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis, and monitoring of
complex autoimmune and autoimmune-related diseases, including
rheumatoid arthritis and lupus.
For more information, please visit Exagen.com and follow
@ExagenInc on Twitter.
CONTACTS:
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024